1999
DOI: 10.1007/s002770050527
|View full text |Cite
|
Sign up to set email alerts
|

Treatment-related chronic myelogenous leukemia

Abstract: Treatment-related (Tr) AML and MDS after chemotherapy, radiotherapy, or the combination of both have been well characterized. However, tr-CML seems to differ from these better-known entities in frequency, clinical course, and prognosis. Tr-CML cannot be distinguished from de novo CML cytogenetically, and, in contrast to tr-AML and tr-MDS, typical chromosomal aberrations related to tr-CML have not been described. Treatment-related CML is a late effect of cytotoxic or immunosuppressive therapy which might be inc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
41
0
2

Year Published

2001
2001
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(43 citation statements)
references
References 102 publications
0
41
0
2
Order By: Relevance
“…In addition to the well-known t-AML and t-MDS, an increasing number of cases of therapy-related CML (t-CML) have been reported after primary hematological malignancies such as Hodgkin lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, as well as solid tumors including ovarian cancer, breast cancer, uterine cervical cancers, etc. [6,7]. t-CML was reported to account for about 13.3 % cases in secondary leukemias [5].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition to the well-known t-AML and t-MDS, an increasing number of cases of therapy-related CML (t-CML) have been reported after primary hematological malignancies such as Hodgkin lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, as well as solid tumors including ovarian cancer, breast cancer, uterine cervical cancers, etc. [6,7]. t-CML was reported to account for about 13.3 % cases in secondary leukemias [5].…”
Section: Discussionmentioning
confidence: 99%
“…Preceding radiotherapy, chemotherapy and immunosuppressive therapy are recognized as major risk factors for the development of t-CML. The time to develop a clinical identifiable t-CML varies greatly, and is supposed to be dependent on preceding malignancies and prior treatment options [7]. Clinical outcome of t-CML patients may be favorable if imatinib-based targeted therapy is applied [8].…”
Section: Discussionmentioning
confidence: 99%
“…Radiobiology is highly suited for dissecting mechanistic CML studies because ionizing radiation, which is known to induce CML 23 that appears indistinguishable from background CML, 24 is an unusually well-understood carcinogen, especially at small time and length scales. The following radiation properties have been characterized and mathematically modeled with relatively high precision: radiation track structure (reviewed in Friedland 25 ); micro-and nanodosimetry (reviewed in Grosswendt et al 26 and Hei et al 27 ); inter-and intratissue dose distributions, such as human dose-volume histograms 28 ; radiation action at submillisecond times (reviewed in Wardman 29 ); subsequent DNA damage-repairmisrepair mechanisms 30 ; DNA damage-processing outcomes (eg, chromosomal aberrations, 31 which are especially important here because of their relevance to BCR-ABL translocations, 32 gene mutations, 33 and transcriptome changes 34 ); and many additional relevant end points.…”
Section: Radiobiologymentioning
confidence: 99%
“…The time range from initial diagnosis of the primary malignancy to tr-CML was about 1 -16 years in various reports. [6][7][8][9][10] In our case tr-CML developed after 2 years.…”
mentioning
confidence: 99%
“…4 It is well known that topoisomerase-II inhibitors and alkylating agents have leukemogenic potential. [5][6] Cancer patients with solid tumors developing tr-CML, used chemotherapies such as cisplatin, bleomycin, cetuximab and 5-fluorouracil. The time range from initial diagnosis of the primary malignancy to tr-CML was about 1 -16 years in various reports.…”
mentioning
confidence: 99%